ARTICLE | Clinical News
Allotrap 2702: Began Phase II trial
March 28, 1994 8:00 AM UTC
SangStat Medical Corp. (SANG), Menlo Park, Calif. Product: Allotrap 2702 peptide made from soluble HLA antigens; binds to and deactivates T cells, allowing graft acceptance Indication: Kidney transpl...